 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

StockNews.com downgraded shares of Ocular Therapeutix (NASDAQ:OCUL  Free Report) from a hold rating to a sell rating in a research report released on Wednesday morning. A number of other...

Ocular Therapeutix (NASDAQ:OCUL) Downgraded by StockNews.com to "Sell"

Ocular Therapeutix (NASDAQ:OCUL  Get Free Report) was upgraded by stock analysts at StockNews.com from a sell rating to a hold rating in a report released on...

Ocular Therapeutix (NASDAQ:OCUL) Lifted to "Hold" at StockNews.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2023 Earnings Call Transcript November 7, 2023 Ocular Therapeutix, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.27...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2023 Earnings Call Transcript

BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...

Ocular Therapeutix  to Present at Three Upcoming Investor Conferences

FDA Agrees to Overall Design of the First Pivotal Trial for AXPAXLI in Wet AMD under a Special Protocol Assessment; Expect First Subject Dosed by Year-End Top-line Data from U.S.-based HELIOS Trial...

Ocular Therapeutix  Provides Third Quarter 2023 Financial Results and Corporate Update

OCUL's total volume now sits at 3.9M. The +11.93% price change was insignificant, leaving IBM's price at $3.19...

The volume for Ocular Therapeutix stock increased for one day, resulting in a record-breaking daily growth of 225% of the 65-Day Volume Moving Average

This is a signal that OCUL's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Ocular Therapeutix (OCUL, $3.19) RSI Indicator left the overbought zone on November 01, 2023

This is a signal that OCUL's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Ocular Therapeutix (OCUL, $3.19) Stochastic Oscillator left the overbought zone on November 01, 2023

The first subject expected to be dosed by year-end Company announces OTX-TKI trade name AXPAXLI BEDFORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a...

Ocular Therapeutix  Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

Ocular Therapeutix gains after FDA agreement for pivotal trial...

Ocular Therapeutix gains after FDA agreement for pivotal trial

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Watchers	10,360
52-Wk Low	$2.00
52-Wk High	$7.96

Market Cap	$203.31M
Volume (M)	1.07M
52-Wk High	$7.96
52-Wk Low	$2.00

OCUL Ocular Therapeutix Inc

About

Feed

News

Sentiment

Earnings

Fundamentals